{"page":{"totalFilteredElements":88},"studies":[{"active":true,"description":"Evaluation der DIGA consilium care bei Patientinnen mit Her 2 positiven Brustkrebs w&#228;hrend einer Chemotherapie in Kombination mit einer Her 2 zielgerichteten Antik&#246;rper Therapie","eudractNumber":null,"id":8562,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05425550","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-06-01T14:29:03+02:00","shortTitle":"PRO2","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>PROstate CAncer Real World Evidence Registry: Registerstudie zur Erfassung des Therapie- und Krankheitsverlaufs bei Patienten mit rezidiviertem und metastasiertem Prostatakrebs</div><div><br /></div><div>DRKS00033411</div>","eudractNumber":null,"id":10394,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-11-07T09:20:45+01:00","shortTitle":"PROCARE","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Real world experience of patients with metastatic castration resistant prostate Cancer treated with Olaparib+Abiraterone","eudractNumber":null,"id":9252,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-01T14:32:33+01:00","shortTitle":"PROCEED","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">Prophylaktische\nWirkung eines retromuskul&#228;ren Netzes w&#228;hrend Ileostomar&#252;ckverlagerung auf die\nInzidenz von Narbenhernien &#8211; eine multizentrische randomisierte Patienten- und\nBeobachter-verblindete Studie</p>\n\n(P.E.L.I.O.N.\nTrial)<div>DRKS00027921</div>","eudractNumber":null,"id":9368,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-03-04T12:15:13+01:00","shortTitle":"Pelion","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Anwendung von Privigen&#174; bei sekund&#228;rer Immunschw&#228;che: Eine multizentrische Beobachtungsstudie (IgPro10_5008)<div><br /></div><div>NIS-Nr.:742</div>","eudractNumber":null,"id":9261,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-02-15T13:25:54+01:00","shortTitle":"Privigen","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<p class=\"MsoNormal\">NAFLD Kohorte Dr. Rau - Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung\n(Fettleberkohorte)</p>","eudractNumber":null,"id":2264,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-10-01T09:40:27+02:00","shortTitle":"Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung (Fettleberkohorte)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospektive NIS of trastuzumab Deruxtecan (T-DXd) for adult patients with advanced HER2-positive gastric or Gastroesophageal junction adenocarcinoma who have received a prior Tratsuzumab based regimen , accompanied by a disease registry of patients treated with conventional therapies in a real world setting","eudractNumber":null,"id":10657,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-04-24T13:38:31+02:00","shortTitle":"Prosperity","therapeutical":false,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Qualit&#228;tssicherung der Therapie des Ovarialkarzinoms (QS-OVAR)&#160;<div>DRKS00027253<div>DRKS00027253DRKS00027253</div></div>","eudractNumber":null,"id":8573,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-06-03T12:47:13+02:00","shortTitle":"QS - OVAR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<b>Erhebung Ovarialmalignom (QS-OVAR 2025)</b>","eudractNumber":null,"id":12316,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-01T10:44:45+01:00","shortTitle":"QS - OVAR 2025","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Evaluation of Clinical Management and Outcome in High\nRisk or Recurrent Endometrial Cancer - A Real-World \nObservational Study (QS-Endometrium)&#160;<div>RETROSPEKTIV</div>","eudractNumber":null,"id":11933,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-27T10:46:24+01:00","shortTitle":"QS-Endometrium","therapeutical":false,"therapyLines":[]}]}